- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03786120
The Efficacy of Lower Dose Zolpidem for Achieving Satisfactory Sleep in Women With Disordered Sleep
April 3, 2019 updated by: Angela Jarman, Rhode Island Hospital
Sleep difficulties are very common in adults in the U.S. today.
Zolpidem (Ambien) is often prescribed as a first line agent to treat sleep difficulties in patients presenting with sleep related complaints to Primary Care Practitioners (PCP's).
Zolpidem is currently available in two doses, 10 and 5 mg.
These doses were developed in clinical studies carried out primarily on men.
The first dose made clinically available, 10 mg, resulted in morbidity and mortality in many women because women metabolize Zolpidem at a slower rate than men, thus the half-life is longer.
Women taking Zolpidem often had morning drowsiness, persistent sleepiness, and difficulty with tasks requiring coordination and judgement, such as motor vehicle operation.
There were a number of well publicized motor vehicle crashes and fatalities attributed to Zolpidem, mostly among women.
The company then produced a 5 mg dose; however, some women still reported side effects at the lower dose, suggesting persistent drug levels in the morning, when the drug purportedly should have been cleared from the body.
These women would likely benefit from a lower dose, a dose personalized for their individual metabolisms and sleep difficulties.
Lower doses of Zolpidem are only available from compounding pharmacies, which are not common, are expensive, do not take many insurances, and are not offered as an option to most patients.
Vitae Industries, Inc. is a start-up tech company located in Providence, founded by a Brown University graduate, a chemical engineer, who has developed technology that can provide precisely varied amounts of drug for specific and variable personalized patient dosing.
Personalized medicine is an area of great research and clinical interest to the medical community at large and the Brown University Medical School in particular.
Brown also has a growing focus on issues of sex and gender in the rendering of clinical medical care.
This technology has the potential to address both of these areas, providing the possibility of very specific, tailored drug dosing for men and women.
This research was developed as a proof of concept study which will be carried out as a collaboration between Brown University Medical School/Lifespan physicians and the technical staff at Vitae Industries, Inc..
This work will be foundational and will serve as the medical and scientific justification for Vitae Industry's providing patient specific dosing of medications.
For the purposes of this study, the medication to be tested, Zolpidem (Ambien) will be compounded by a licensed compounding Rhode Island pharmacy, PhusionRx, using standardized approaches to compounding and formulating pharmaceutical products.
This study will use low doses of Zolpidem formulated by the licensed compounding pharmacy, PhusionRx.
The investigators will provide graduated doses of Zolpidem to women participants meeting inclusion criteria who present to their primary care physician complaining of difficulty achieving satisfactory sleep.
Participants will start at a dose of 0.5 mg of Zolpidem.
Each day the quality of their sleep will be assessed by self-report.
If they have not achieved satisfactory sleep at the starting dose of 0.5 mg, the will increase their dose daily by 0.5 mg until they reach the standard 5 mg dose or satisfactory sleep is achieved.
Study Overview
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Angela Jarman, MD MPH
- Phone Number: 9196327961
- Email: angela.jarman@gmail.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95819
- Recruiting
- Rhode Island Hospital
-
Contact:
- Angela Jarman
- Phone Number: 919-632-7961
- Email: angela.jarman@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Health Women with Disordered Sleep
Description
Inclusion Criteria:
- biologically female
- age 18-65
- English speaking
- difficulty sleeping
Exclusion Critieria:
- diagnosed significant cardiac, pulmonary, neuromuscular, hepatic, renal or major psychiatric disease (as ascertained by the study physicians)
- diagnosed sleep pathology such as sleep apnea or prior work-up for sleep pathology
- recent (two weeks prior) treatment of any kind for sleep disorder including herbal or over the counter treatments, psychiatric medications including anxiolytics except for SSRI's.
- pregnant or trying to become pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
First 25 subjects
|
PO sleep aid in various doses
|
2
Second cohort of 25 subjects
|
PO sleep aid in various doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Quality
Time Frame: 7 days
|
This will be based on the sleep journal
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Side Effects
Time Frame: 7 days
|
Including daytime drowsiness, night walking/eating
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce Becker, MD, Lifespan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2019
Primary Completion (Anticipated)
July 31, 2019
Study Completion (Anticipated)
December 31, 2019
Study Registration Dates
First Submitted
January 24, 2018
First Submitted That Met QC Criteria
December 20, 2018
First Posted (Actual)
December 24, 2018
Study Record Updates
Last Update Posted (Actual)
April 8, 2019
Last Update Submitted That Met QC Criteria
April 3, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Sleep Wake Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- Ambien Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorder
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
-
Johannes Gutenberg University MainzRecruitingSleep Disorder | Restless Legs Syndrome | Insomnia | Sleep Apnea | Narcolepsy | Idiopathic Hypersomnia | Somnambulism | Sleep Disorder Parasomnia | REM Behavior DisorderGermany
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
Vanda PharmaceuticalsRecruitingSleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological DisorderUnited States
-
Assistance Publique Hopitaux De MarseilleAix Marseille UniversitéRecruitingREM Sleep Behaviour DisorderFrance
-
Massachusetts General HospitalRecruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCritical Illness | Sleep Deprivation | Circadian Rhythm Sleep Disorder, UnspecifiedUnited States
Clinical Trials on Zolpidem
-
EMSAssociação Fundo de Incentivo à PesquisaCompleted
-
Henry Ford Health SystemCompleted
-
University of PennsylvaniaNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedInsomnia | Insomnia ChronicUnited States
-
Biolab Sanus FarmaceuticaCompleted
-
Biolab Sanus FarmaceuticaCompleted
-
TakedaCompletedChronic InsomniaUnited States
-
Eisai Inc.Purdue Pharma LPCompleted
-
Eisai Inc.CompletedInsomniaUnited States, Spain, United Kingdom, Italy, Germany, France, Canada
-
Mutual Pharmaceutical Company, Inc.CompletedHealthy | Therapeutic Equivalency
-
Astellas Pharma IncAstellas Pharma Taiwan, Inc.CompletedSleep Initiation and Maintenance Disorders | Primary InsomniaTaiwan